Eli Lilly and Company's Revenue
- Eli Lilly and Company's annual revenue was $34.12B in fiscal year 2023. The annual revenue increased $5.58B from $28.54B (in 2022) to $34.12B (in 2023), representing a 19.56% year-over-year growth.
- Eli Lilly and Company's quarterly revenue was $11.44B in the quarter ending Sep 2024. The quarterly revenue increased $1.94B from $9.50B (in Q3: June 2023) to $11.44B (in Q3: June 2024), representing a 20.43% year-over-year growth.
- The highest annual revenue for Eli Lilly and Company was $34.12B in fiscal year 2023.
- The lowest annual revenue was $19.96B in fiscal year 2015.
- The average revenue was $24.82B.
- Revenue is the amount of money generated by a business from sales of its goods or services. Refer to our glossary for more details, examples, and formulas.
Over the past 10 years (2015 - 2024):
Learn more about Eli Lilly and Company's Revenue by Segment and Revenue by Region.
Check out competitors to Eli Lilly and Company in a side-by-side comparison.
Explore additional financial metrics for Eli Lilly and Company.
Definition of Revenue :
| 2014 | 19615600000.00 |
|---|---|
| 2015 | 19958700000.00 |
| 2016 | 21222100000.00 |
| 2017 | 22871300000.00 |
| 2018 | 21493300000.00 |
| 2019 | 22319500000.00 |
| 2020 | 24539800000.00 |
| 2021 | 28318400000.00 |
| 2022 | 28541400000.00 |
| 2023 | 34124100000.00 |
| Mar 2015 | 4644700000.00 |
|---|---|
| Jun 2015 | 4978700000.00 |
| Sep 2015 | 4959700000.00 |
| Dec 2015 | 5375600000.00 |
| Mar 2016 | 4865100000.00 |
| Jun 2016 | 5404800000.00 |
| Sep 2016 | 5191700000.00 |
| Dec 2016 | 5760500000.00 |
| Mar 2017 | 5228300000.00 |
| Jun 2017 | 5824300000.00 |
| Sep 2017 | 5658000000.00 |
| Dec 2017 | 6160700000.00 |
| Mar 2018 | 5700000000.00 |
| Jun 2018 | 6355200000.00 |
| Sep 2018 | 6061900000.00 |
| Dec 2018 | 6438600000.00 |
| Mar 2019 | 5092200000.00 |
| Jun 2019 | 5636700000.00 |
| Sep 2019 | 5476600000.00 |
| Dec 2019 | 6114000000.00 |
| Mar 2020 | 5859800000.00 |
| Jun 2020 | 5499400000.00 |
| Sep 2020 | 5740600000.00 |
| Dec 2020 | 7440000000.00 |
| Mar 2021 | 6805600000.00 |
| Jun 2021 | 6740100000.00 |
| Sep 2021 | 6772800000.00 |
| Dec 2021 | 7999900000.00 |
| Mar 2022 | 7810000000.00 |
| Jun 2022 | 6488000000.00 |
| Sep 2022 | 6941600000.00 |
| Dec 2022 | 7301800000.00 |
| Mar 2023 | 6960000000.00 |
| Jun 2023 | 8312100000.00 |
| Sep 2023 | 9498600000.00 |
| Dec 2023 | 9353400000.00 |
| Mar 2024 | 8768000000.00 |
| Jun 2024 | 11302800000.00 |
| Sep 2024 | 11439100000.00 |
2023
Eli Lilly and Company's annual revenue was $34.12B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $6.96B(Q1: Mar 2023), $8.31B(Q2: Jun 2023), $9.50B(Q3: Sep 2023), $9.35B(Q4: Dec 2023) in fiscal year 2023.
2022
Eli Lilly and Company's annual revenue was $28.54B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $7.81B(Q1: Mar 2022), $6.49B(Q2: Jun 2022), $6.94B(Q3: Sep 2022), $7.30B(Q4: Dec 2022) in fiscal year 2022.
2021
Eli Lilly and Company's annual revenue was $28.32B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $6.81B(Q1: Mar 2021), $6.74B(Q2: Jun 2021), $6.77B(Q3: Sep 2021), $8.00B(Q4: Dec 2021) in fiscal year 2021.
2020
Eli Lilly and Company's annual revenue was $24.54B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $5.86B(Q1: Mar 2020), $5.50B(Q2: Jun 2020), $5.74B(Q3: Sep 2020), $7.44B(Q4: Dec 2020) in fiscal year 2020.
2019
Eli Lilly and Company's annual revenue was $22.32B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $5.09B(Q1: Mar 2019), $5.64B(Q2: Jun 2019), $5.48B(Q3: Sep 2019), $6.11B(Q4: Dec 2019) in fiscal year 2019.
2018
Eli Lilly and Company's annual revenue was $21.49B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $5.70B(Q1: Mar 2018), $6.36B(Q2: Jun 2018), $6.06B(Q3: Sep 2018), $6.44B(Q4: Dec 2018) in fiscal year 2018.
2017
Eli Lilly and Company's annual revenue was $22.87B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $5.23B(Q1: Mar 2017), $5.82B(Q2: Jun 2017), $5.66B(Q3: Sep 2017), $6.16B(Q4: Dec 2017) in fiscal year 2017.
2016
Eli Lilly and Company's annual revenue was $21.22B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $4.87B(Q1: Mar 2016), $5.40B(Q2: Jun 2016), $5.19B(Q3: Sep 2016), $5.76B(Q4: Dec 2016) in fiscal year 2016.
2015
Eli Lilly and Company's annual revenue was $19.96B in fiscal year 2023.
Eli Lilly and Company's quarterly revenue was $4.64B(Q1: Mar 2015), $4.98B(Q2: Jun 2015), $4.96B(Q3: Sep 2015), $5.38B(Q4: Dec 2015) in fiscal year 2015.
| 2014 | 0 |
|---|---|
| 2015 | +1.75 |
| 2016 | +6.33 |
| 2017 | +7.77 |
| 2018 | -6.03 |
| 2019 | +3.84 |
| 2020 | +9.95 |
| 2021 | +15.40 |
| 2022 | +0.79 |
| 2023 | +19.56 |
| Q1: Mar 15 | -0.82 |
|---|---|
| Q2: Jun 15 | 0.87 |
| Q3: Sep 15 | 1.72 |
| Q4: Dec 15 | 4.97 |
| Q1: Mar 16 | 4.75 |
| Q2: Jun 16 | 8.56 |
| Q3: Sep 16 | 4.68 |
| Q4: Dec 16 | 7.16 |
| Q1: Mar 17 | 7.47 |
| Q2: Jun 17 | 7.76 |
| Q3: Sep 17 | 8.98 |
| Q4: Dec 17 | 6.95 |
| Q1: Mar 18 | 9.02 |
| Q2: Jun 18 | 9.12 |
| Q3: Sep 18 | 7.14 |
| Q4: Dec 18 | 4.51 |
| Q1: Mar 19 | -10.66 |
| Q2: Jun 19 | -11.31 |
| Q3: Sep 19 | -9.66 |
| Q4: Dec 19 | -5.04 |
| Q1: Mar 20 | 15.07 |
| Q2: Jun 20 | -2.44 |
| Q3: Sep 20 | 4.82 |
| Q4: Dec 20 | 21.69 |
| Q1: Mar 21 | 16.14 |
| Q2: Jun 21 | 22.56 |
| Q3: Sep 21 | 17.98 |
| Q4: Dec 21 | 7.53 |
| Q1: Mar 22 | 14.76 |
| Q2: Jun 22 | -3.74 |
| Q3: Sep 22 | 2.49 |
| Q4: Dec 22 | -8.73 |
| Q1: Mar 23 | -10.88 |
| Q2: Jun 23 | 28.11 |
| Q3: Sep 23 | 36.84 |
| Q4: Dec 23 | 28.10 |
| Q1: Mar 24 | 25.98 |
| Q2: Jun 24 | 35.98 |
| Q3: Sep 24 | 20.43 |
2023
Eli Lilly and Company’s annual revenue increased +19.56% during fiscal year 2023 compared to 2022. It represents a growth of $5.58B from $28.54B (in 2022) to $34.12B (in 2023).
2022
Eli Lilly and Company’s annual revenue increased +0.79% during fiscal year 2022 compared to 2021. It represents a growth of $223.00M from $28.32B (in 2021) to $28.54B (in 2022).
2021
Eli Lilly and Company’s annual revenue increased +15.40% during fiscal year 2021 compared to 2020. It represents a growth of $3.78B from $24.54B (in 2020) to $28.32B (in 2021).
2020
Eli Lilly and Company’s annual revenue increased +9.95% during fiscal year 2020 compared to 2019. It represents a growth of $2.22B from $22.32B (in 2019) to $24.54B (in 2020).
2019
Eli Lilly and Company’s annual revenue increased +3.84% during fiscal year 2019 compared to 2018. It represents a growth of $826.20M from $21.49B (in 2018) to $22.32B (in 2019).
2018
Eli Lilly and Company’s annual revenue decreased -6.03% during fiscal year 2018 compared to 2017. It represents a decline of -$1.38B from $22.87B (in 2017) to $21.49B (in 2018).
2017
Eli Lilly and Company’s annual revenue increased +7.77% during fiscal year 2017 compared to 2016. It represents a growth of $1.65B from $21.22B (in 2016) to $22.87B (in 2017).
2016
Eli Lilly and Company’s annual revenue increased +6.33% during fiscal year 2016 compared to 2015. It represents a growth of $1.26B from $19.96B (in 2015) to $21.22B (in 2016).
2015
Eli Lilly and Company’s annual revenue increased +1.75% during fiscal year 2015 compared to 2014. It represents a growth of $343.10M from $19.62B (in 2014) to $19.96B (in 2015).
Summary Table (Annual)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| 2023 | $34.12B | +19.56% |
| 2022 | $28.54B | +0.79% |
| 2021 | $28.32B | +15.40% |
| 2020 | $24.54B | +9.95% |
| 2019 | $22.32B | +3.84% |
| 2018 | $21.49B | -6.03% |
| 2017 | $22.87B | +7.77% |
| 2016 | $21.22B | +6.33% |
| 2015 | $19.96B | +1.75% |
Summary Table (Quarterly)
| Period | Revenue | Year-over-Year Change |
|---|---|---|
| Q3: Sep 24 | $11.44B | 20.43% |
| Q2: Jun 24 | $11.30B | 35.98% |
| Q1: Mar 24 | $8.77B | 25.98% |
| Q4: Dec 23 | $9.35B | 28.10% |
| Q3: Sep 23 | $9.50B | 36.84% |
| Q2: Jun 23 | $8.31B | 28.11% |
| Q1: Mar 23 | $6.96B | -10.88% |
| Q4: Dec 22 | $7.30B | -8.73% |
| Q3: Sep 22 | $6.94B | 2.49% |
| Q2: Jun 22 | $6.49B | -3.74% |
| Q1: Mar 22 | $7.81B | 14.76% |
| Q4: Dec 21 | $8.00B | 7.53% |
| Q3: Sep 21 | $6.77B | 17.98% |
| Q2: Jun 21 | $6.74B | 22.56% |
| Q1: Mar 21 | $6.81B | 16.14% |
| Q4: Dec 20 | $7.44B | 21.69% |
| Q3: Sep 20 | $5.74B | 4.82% |
| Q2: Jun 20 | $5.50B | -2.44% |
| Q1: Mar 20 | $5.86B | 15.07% |
| Q4: Dec 19 | $6.11B | -5.04% |
| Q3: Sep 19 | $5.48B | -9.66% |
| Q2: Jun 19 | $5.64B | -11.31% |
| Q1: Mar 19 | $5.09B | -10.66% |
| Q4: Dec 18 | $6.44B | 4.51% |
| Q3: Sep 18 | $6.06B | 7.14% |
| Q2: Jun 18 | $6.36B | 9.12% |
| Q1: Mar 18 | $5.70B | 9.02% |
| Q4: Dec 17 | $6.16B | 6.95% |
| Q3: Sep 17 | $5.66B | 8.98% |
| Q2: Jun 17 | $5.82B | 7.76% |
| Q1: Mar 17 | $5.23B | 7.47% |
| Q4: Dec 16 | $5.76B | 7.16% |
| Q3: Sep 16 | $5.19B | 4.68% |
| Q2: Jun 16 | $5.40B | 8.56% |
| Q1: Mar 16 | $4.87B | 4.75% |
| Q4: Dec 15 | $5.38B | 4.97% |
| Q3: Sep 15 | $4.96B | 1.72% |
| Q2: Jun 15 | $4.98B | 0.87% |
| Q1: Mar 15 | $4.64B | -0.82% |
Related
-
Agilent Technologies Revenue
-
Stryker Corporation Revenue
-
Johnson & Johnson Revenue
-
AbbVie Revenue
-
Merck & Co. Revenue
-
Thermo Fisher Scientific Revenue
-
Abbott Laboratories Revenue
-
Danaher Corporation Revenue
-
Amgen Revenue
-
Pfizer Revenue
-
Boston Scientific Corporation Revenue
-
Bristol-Myers Squibb Company Revenue
-
Cigna Corporation Revenue
-
McKesson Corporation Revenue
-
Cardinal Health Revenue
-
Moderna Revenue
